Company Announcements

Trading update

Source: RNS
RNS Number : 0733B
Synthomer PLC
29 September 2022
 

29th September 2022

 

Synthomer plc

 

Trading update

 

Synthomer plc ('Synthomer' or 'the Group') today provides an update on current trading and its outlook for Full Year 2022.

 

At the time of its interim results in August, the Group reported that inventory levels of medical gloves remained high post-pandemic with reduced demand. The associated de-stocking significantly reduced nitrile butadiene rubber (NBR) production volumes in H1 and delayed a return to pre-pandemic NBR growth.

 

During the third quarter, this de-stocking has continued with production volumes further reduced. The Board now anticipates modest profitability in Performance Elastomers for the second half of the year. Whilst underlying end-customer demand for medical gloves remains similar to pre-COVID levels, the destocking impact is not expected to abate before the end of 2023.

 

The Group also highlighted at its interim results the challenging macroeconomic environment. Since August, macroeconomic conditions have deteriorated, leading to reduced demand in construction and coatings end markets. This has impacted trading in Synthomer's European business.

 

As a result of these factors, the Board now expects Full Year EBITDA to be 10% to 15% below its previous expectations. 

 

The Group is focused on deleveraging and cash generation and is progressing a number of strategic initiatives and operational actions to reduce costs, capital expenditure and, as indicated in August, working capital.

 

Synthomer will host an event for investors and analysts on 12th October 2022 where it will provide an update on strategy and the Group's new Adhesive Technologies division.

 

-ENDS-

 

Enquiries:

 

Investors: Tim Hughes, Synthomer         07764 859 147              

Press: Charlie Armitstead, Teneo            07703 330 269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZGZLNRNGZZM